Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer - Top-Institutions - MDSpire

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

  • By

  • Chuan Angel Lu

  • Changchuan Jiang

  • Andrew Z. Wang

  • Tian Zhang

  • May 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, Texas

    Key Differentiators

    • Oncology

  • #2

    Massachusetts General Brigham Health System
    Massachusetts General Brigham Health System

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology

  • #4

    University of Milan
    University of Milan

    Milan, Italy

    Key Differentiators

    • Oncology

  • #5

    European Institute of Oncology
    European Institute of Oncology

    Milan, Italy

    Key Differentiators

    • Oncology

Original Source(s)

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

  • by Chuan Angel Lu, Changchuan Jiang, Andrew Z. Wang, Tian Zhang

  • May 29, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026